Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Eli Lilly’s experimental oral weight loss pill helped patients lose about 12 percent of their body weight on average in a late-stage trial, the company said Thursday, positive results but still ...

Eli Lilly (NYSE: LLY) posted a 38% jump in revenue to $15.6 billion in the second quarter of 2025, driven by surging demand ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Eli Lilly’s weight-loss pill, orforglipron, shows promising results in trials, offering a needle-free alternative to injectables like Ozempic and Mounjaro. In a major study, people who took the drug ...

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

To make things a little less confusing, we’re here with all the info you need about popular weight loss med Mounjaro.

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach? Medical experts weigh in.

Ithaka Group unpacks Q2’s portfolio drivers - from AI surges to tariff shocks. See which stocks moved the needle and what it ...

Results involving the highest dose of orforglipron disappointed investors — but still bring the drug a step closer to ...

Primary packaging is never an afterthought in the world of injectable drugs, where systems such as vials, syringes, and auto-injectors are crucial to the administration of new products. But what ...

Eli Lilly says its experimental GLP-1 pill helped patients lose 12.4 per cent of their body weight after 72 weeks in a ...